Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xenetic BiosciencesXBIO +11.23%84 Cyclically Adjusted PS Ratio is 0.11 as of Aug. 08, 2026, which is at its 10-year median of 0.11. GuruFocus rates XBIO with a GF Score™ of 84/100 and a GF Value™ of $4.24 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 537 Biotechnology companies, Xenetic Biosciences ranks better than 96.65% on this metric.
The historical rank and industry rank for Xenetic Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:
XBIO'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.06 Med: 0.11 Max: 0.78
Current: 0.1
During the past years, Xenetic Biosciences's highest Cyclically Adjusted PS Ratio was 0.78. The lowest was 0.06. And the median was 0.11.
XBIO's Cyclically Adjusted PS Ratio is ranked better than 96.65% of 537
companies
in the Biotechnology industry
Industry Median: 5.5
vs XBIO: 0.10
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Xenetic Biosciences's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.352. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $28.68 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Xenetic Biosciences (NAS:XBIO) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Xenetic Biosciences Cyclically Adjusted PS Ratio Related Terms
Xenetic Biosciences Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences Cyclically Adjusted PS Ratio Chart
XBIO vs ADIL, PULM, KAPA: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Xenetic Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Cyclically Adjusted PS Ratio falls into.
Xenetic Biosciences Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Xenetic Biosciences's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.11 mean?
Xenetic Biosciences (XBIO) has a Cyclically Adjusted PS Ratio of 0.11 as of Aug. 08, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors. This is near median its historical median of 0.11. Over the past decade, Xenetic Biosciences' Cyclically Adjusted PS Ratio has ranged from 0.06 to 0.78. According to the industry distribution chart, Xenetic Biosciences ranks #18 out of 537 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Xenetic Biosciences' Cyclically Adjusted PS Ratio too high?
Xenetic Biosciences' current Cyclically Adjusted PS Ratio of 0.11 is near median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.78. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.50. Xenetic Biosciences' value of 0.11 is 98% below this industry median. Based on the distribution chart, Xenetic Biosciences ranks #18 out of 537 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xenetic Biosciences has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Cyclically Adjusted PS Ratio compare to ADIL and PULM?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #18 out of 537 companies for Cyclically Adjusted PS Ratio. This places Xenetic Biosciences in the top 3% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 5.50. Xenetic Biosciences' value of 0.11 is 98% below this benchmark. Historically, Xenetic Biosciences' own Cyclically Adjusted PS Ratio has ranged from 0.06 to 0.78 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 5.50, Xenetic Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.50, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xenetic Biosciences's current Cyclically Adjusted PS Ratio of 0.11 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xenetic Biosciences and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenetic Biosciences's current Cyclically Adjusted PS Ratio is 0.11, which is near median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.24, compared to a current price of $3.20 — trading 24.5% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.11, which is near median its 10-year median of 0.11 and 98% below the Biotechnology industry median of 5.50. Xenetic Biosciences' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Cyclically Adjusted PS Ratio is 0.11 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $3.20 is trading 24.5% below its estimated GF Value™ of $4.24.
GuruFocus considers Xenetic Biosciences to be Modestly Undervalued.
Key valuation signals for XBIO:
Cyclically Adjusted PS Ratio: 0.11 (near median its 10-year median of 0.11)
GF Value™: $4.24 vs. price of $3.20 (24.5% below fair value)
Industry Position: 98% below the Biotechnology median (#18 of 537)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
84GF Score
Get the complete analysis for XBIO
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
